Rigel Pharma (RIGL) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $51.29 +4.97%
Revenue Growth %: +15.2%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
CIX, ARIS, COHR, More
Revenue Growth %: +15.2%
Financial Fact:
General and administrative: 4.56M
Today's EPS Names:
CIX, ARIS, COHR, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q1 EPS of ($0.05), $0.02 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $29.53 million versus the consensus estimate of $31.48 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viemed Healthcare, Inc. (VMD) Misses Q3 EPS by 2c; updates guidance
- Aris Water Solutions (ARIS) Tops Q3 EPS by 35c
- Myriad Genetics (MYGN) Tops Q3 EPS by 9c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
